Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study

Ann Oncol. 2019 Dec 1;30(12):2010. doi: 10.1093/annonc/mdz222.
No abstract available

Publication types

  • Published Erratum